Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CNTA
- Price
- 11.27
- Stock movement down
- -0.49 (-4.17%)
- Company name
- Centessa Pharmaceuticals PLC ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.49B
- Ent value
- 1.20B
- Price/Sales
- 214.95
- Price/Book
- 2.98
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -0.31%
- 3 year return
- 5.60%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CNTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 214.95 |
| Price to Book | 2.98 |
| EV to Sales | 173.80 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 131.84M |
| EPS (TTM) | -1.39 |
| FCF per share (TTM) | -1.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.91M |
| Gross profit (TTM) | 5.95M |
| Operating income (TTM) | -161.99M |
| Net income (TTM) | -161.61M |
| EPS (TTM) | -1.39 |
| EPS (1y forward) | -1.56 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 86.10% |
| Operating margin (TTM) | -2343.36% |
| Profit margin (TTM) | -2337.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 395.03M |
| Net receivables | 40.04M |
| Total current assets | 568.36M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 609.72M |
| Accounts payable | 7.44M |
| Short/Current long term debt | 84.72M |
| Total current liabilities | 26.41M |
| Total liabilities | 110.58M |
| Shareholder's equity | 499.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -127.04M |
| Capital expenditures (TTM) | 62.03K |
| Free cash flow (TTM) | -127.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -32.38% |
| Return on Assets | -26.51% |
| Return on Invested Capital | -32.34% |
| Cash Return on Invested Capital | -25.43% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.74 |
| Daily high | 11.78 |
| Daily low | 10.45 |
| Daily Volume | 1.31M |
| All-time high | 25.66 |
| 1y analyst estimate | 28.57 |
| Beta | 1.48 |
| EPS (TTM) | -1.39 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CNTA | S&P500 | |
| Current price drop from All-time high | -56.08% | -14.41% |
| Highest price drop | -88.19% | -56.47% |
| Date of highest drop | 16 Feb 2023 | 9 Mar 2009 |
| Avg drop from high | -61.18% | -11.07% |
| Avg time to new high | 324 days | 12 days |
| Max time to new high | 959 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.49B
Marketcap category
Small-cap
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Employees
76
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page